Treatment-Resistant Depression

Technology

Last mentioned: Mar 8, 2026

Timeline

Jun 30, 2027
Enrollment Milestone

Estimated completion of patient enrollment for the global Phase 3 study.
Apr 1, 2026
Phase 3 Launch Window

Expected start of the pivotal Phase 3 trial for Treatment-Resistant Depression.
Mar 8, 2026
Earnings & Timeline Release

Company announces 2025 results and sets Q2 2026 for BPL-003 Phase 3 launch.
Dec 31, 2025
FY 2025 Close

End of the fiscal year reporting period for AtaiBeckley.

Stories mentioning Treatment-Resistant Depression 1

AtaiBeckley to Launch Phase 3 BPL-003 Trial Following Strong 2025 Results

AtaiBeckley (ATAI) has confirmed the Q2 2026 launch of its Phase 3 program for BPL-003, an intranasal 5-MeO-DMT formulation for Treatment-Resistant Depression. The announcement follows the release of 2025 financial results that show a robust cash position capable of funding pivotal late-stage clinical development.

Mar 8, 2026 2 sources